Chart-Typ:
Zeitraum:
| Aktien Europa: Kaum verändert - Hochstufung treibt DocMorris-Aktie an | PARIS/LONDON/ZÜRICH (dpa-AFX) - Der nach wie vor zugespitzte Konflikt zwischen den USA und dem Iran hat die Anleger an Europas Börsen am Montag nicht sonderlich verunsichert. "Es ist die Wiederholung... ► Artikel lesen |
| AKTIEN IM FOKUS: Chip- und KI-Titel leiden unter asiatischer Tech-Schwäche | FRANKFURT/PARIS (dpa-AFX) - Halbleiter- und KI-Aktien sind am Montag von der Tech-Schwäche in Südkorea und Japan mit nach unten gezogen worden. Die dortigen Leitindizes Kospi und Nikkei 225 büßten... ► Artikel lesen |
| CAC 40 Up Slightly At Noon; STMicroelectronics, Societe Generale Rise Sharply | BRUSSELS (dpa-AFX) - Despite concerns about the ongoing conflict between Iran and the U.S. the French market was up slightly Thursday morning with investors picking up some stocks at reduced... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen |
| Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings | BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA)... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STARDUST POWER INC finden Sie auf Wallstreet Online.